Notice: This company has been marked as potentially delisted and may not be actively trading. Flex Pharma (FLKS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends FLKS vs. NVCT, VERU, INZY, ENTA, IGMS, MIST, OSTX, COYA, BHST, and MNOVShould you be buying Flex Pharma stock or one of its competitors? The main competitors of Flex Pharma include Nuvectis Pharma (NVCT), Veru (VERU), Inozyme Pharma (INZY), Enanta Pharmaceuticals (ENTA), IGM Biosciences (IGMS), Milestone Pharmaceuticals (MIST), OS Therapies (OSTX), Coya Therapeutics (COYA), BioHarvest Sciences (BHST), and MediciNova (MNOV). These companies are all part of the "medical" sector. Flex Pharma vs. Nuvectis Pharma Veru Inozyme Pharma Enanta Pharmaceuticals IGM Biosciences Milestone Pharmaceuticals OS Therapies Coya Therapeutics BioHarvest Sciences MediciNova Nuvectis Pharma (NASDAQ:NVCT) and Flex Pharma (NASDAQ:FLKS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership. Does the MarketBeat Community believe in NVCT or FLKS? Flex Pharma received 352 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 90.00% of users gave Nuvectis Pharma an outperform vote while only 73.23% of users gave Flex Pharma an outperform vote. CompanyUnderperformOutperformNuvectis PharmaOutperform Votes990.00% Underperform Votes110.00%Flex PharmaOutperform Votes36173.23% Underperform Votes13226.77% Do insiders and institutionals hold more shares of NVCT or FLKS? 96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 14.4% of Flex Pharma shares are owned by institutional investors. 35.8% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 7.6% of Flex Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is NVCT or FLKS more profitable? Nuvectis Pharma has a net margin of 0.00% compared to Flex Pharma's net margin of -1,208.42%. Flex Pharma's return on equity of -98.04% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Nuvectis PharmaN/A -155.80% -104.02% Flex Pharma -1,208.42%-98.04%-83.37% Which has higher valuation and earnings, NVCT or FLKS? Flex Pharma has higher revenue and earnings than Nuvectis Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvectis PharmaN/AN/A-$22.26M-$1.16-5.26Flex Pharma$840K53.35-$21.92MN/AN/A Do analysts recommend NVCT or FLKS? Nuvectis Pharma currently has a consensus price target of $21.00, suggesting a potential upside of 244.26%. Given Nuvectis Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Nuvectis Pharma is more favorable than Flex Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Flex Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, NVCT or FLKS? Nuvectis Pharma has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Flex Pharma has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Does the media refer more to NVCT or FLKS? In the previous week, Nuvectis Pharma's average media sentiment score of 0.00 equaled Flex Pharma'saverage media sentiment score. Company Overall Sentiment Nuvectis Pharma Neutral Flex Pharma Neutral SummaryNuvectis Pharma beats Flex Pharma on 7 of the 13 factors compared between the two stocks. Get Flex Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for FLKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLKS vs. The Competition Export to ExcelMetricFlex PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.81M$6.55B$5.39B$9.24BDividend YieldN/A2.96%5.37%3.99%P/E RatioN/A9.8989.1117.52Price / Sales53.35334.651,221.8479.25Price / CashN/A64.1243.6036.96Price / Book4.865.105.014.72Net Income-$21.92M$154.66M$117.81M$224.61M Flex Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLKSFlex PharmaN/A$2.48-7.8%N/A+350.2%$44.81M$840,000.000.004Gap DownNVCTNuvectis Pharma2.9735 of 5 stars$5.81flat$21.00+261.4%-30.3%$112.26MN/A-5.018Positive NewsVERUVeru2.5339 of 5 stars$0.76-2.5%$4.00+424.8%+194.6%$111.57M$16.89M-1.59230Options VolumeINZYInozyme Pharma3.3653 of 5 stars$1.72-13.8%$18.33+965.9%-68.7%$110.49MN/A-1.1050Gap UpENTAEnanta Pharmaceuticals4.3813 of 5 stars$5.03-1.2%$17.25+242.9%-56.3%$106.61M$67.64M-0.92160IGMSIGM Biosciences4.6971 of 5 stars$1.77-15.3%$5.50+210.7%-83.7%$105.25M$2.92M-0.49190Gap UpMISTMilestone Pharmaceuticals2.3228 of 5 stars$1.97-5.3%$13.00+559.9%+52.9%$105.06M$1M-2.4330OSTXOS Therapies2.5577 of 5 stars$4.65-6.4%$8.00+72.0%N/A$100.13MN/A0.00N/ACOYACoya Therapeutics2.6356 of 5 stars$5.97+3.5%$16.25+172.2%-5.2%$99.74M$9.55M-9.186Analyst ForecastNews CoveragePositive NewsBHSTBioHarvest SciencesN/A$6.03-1.1%$13.00+115.6%N/A$99.04M$22.43M-4.83N/ANews CoverageHigh Trading VolumeMNOVMediciNova1.3402 of 5 stars$1.99+1.5%$9.00+352.3%+22.7%$97.60M$1M-9.4810Positive News Related Companies and Tools Related Companies Nuvectis Pharma Competitors Veru Competitors Inozyme Pharma Competitors Enanta Pharmaceuticals Competitors IGM Biosciences Competitors Milestone Pharmaceuticals Competitors OS Therapies Competitors Coya Therapeutics Competitors BioHarvest Sciences Competitors MediciNova Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FLKS) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flex Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Flex Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FLKS Stock Alerts